Paper Details

  1. Home
  2. Paper Details

Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials.

Author: , BethouxFrancois, BlightAndrew R, BrownTheodore R, CohenRon, GoodmanAndrew D, HenneyHerbert R, MarinucciLawrence N, SchapiroRandall T

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study reports the results of two Phase 3 trials (MS-F203 and MS-F204) that investigated the efficacy of dalfampridine extended release tablets in patients with multiple sclerosis (MS). The drug improved walking speed compared to placebo.
Paper Details　
Original Abstract of the Article :
In Phase 3 double-blind trials (MS-F203 and MS-F204), dalfampridine extended release tablets 10 mg twice daily (dalfampridine-ER; prolonged-release fampridine in Europe; fampridine modified or sustained release elsewhere) improved walking speed relative to placebo in patients with multiple sclerosis...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4561451/

データ提供：米国国立医学図書館（NLM）

Dalfampridine for Walking Impairment in Multiple Sclerosis: A Long-Term Perspective

Multiple sclerosis (MS), a chronic neurological disease, can affect a person's ability to walk, making it difficult to navigate the world around them. This study examines the long-term safety and efficacy of dalfampridine, a medication used to improve walking speed in people with MS.

Dalfampridine's Long-Term Benefits: A Steady Journey

The researchers conducted open-label extensions of two Phase 3 trials, following patients who had received dalfampridine for an extended period. Their findings suggest that dalfampridine can provide long-term benefits for walking speed in people with MS, with a favorable safety profile. This is encouraging news, like a desert traveler finding a reliable source of water that can sustain them on their journey.

Managing MS: A Quest for Improved Mobility

This study provides valuable information about the long-term use of dalfampridine for MS patients. It offers hope for those struggling with walking impairment, suggesting that this medication can provide sustained benefits over time. This research, like a guiding star in the desert night, illuminates a path towards improved mobility for people with MS.

Dr. Camel's Conclusion

This study provides evidence that dalfampridine can offer long-term benefits for walking speed in people with MS, with a favorable safety profile. This research is a valuable contribution to the field of MS treatment, offering hope for improved mobility and quality of life for patients.
Date :
  1. Date Completed 2016-08-19
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

25583832

DOI: Digital Object Identifier

PMC4561451

Related Literature

Article Analysis
・Effects of dalfampridine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.